Zobrazeno 1 - 10
of 98
pro vyhledávání: '"Suzanne Berlin"'
Autor:
Michael J. Birrer, Rebecca C. Arend, McKenzie E. Foxall, Hannah M. Beer, Jaclyn A. Wall, Susana M. Campos, Suzanne Berlin, Yael C Cohen, Tamar Rachmilewitz Minei, Richard T. Penson, Dror Harats
Publikováno v:
Gynecologic Oncology. 157:578-584
Objective Report final results of a phase I/II study of VB-111, a targeted anti-cancer gene therapy with a dual mechanism: anti angiogenic/vascular disruption and induction of an anti-tumor directed immune response, in combination with paclitaxel in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45936967b82485c6ebc8bc4a29520c75
https://doi.org/10.1016/j.ygyno.2020.02.034
https://doi.org/10.1016/j.ygyno.2020.02.034
Autor:
Susana Campos, Ursula Matulonis, Suzanne Berlin, Neil Horowitz, Joyce Liu, Carolyn Krasner, Lee Hang, Corrine Zarwan, William Barry, Tina Colella, Christen Whalen, Melina Shoni, Christine Lundquist, Michael J. Birrer, Richard Penson
Publikováno v:
International journal of clinical oncology. 27(12)
The combination of paclitaxel to platinum remains the backbone of therapy in patients with advanced Mullerian tumors. In patients with newly diagnosed Mullerian tumors, we investigated the progression-free survival benefit of bevacizumab and bevacizu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f9fd6521288d6d1e6bd7e6162618271
https://pubmed.ncbi.nlm.nih.gov/36344654
https://pubmed.ncbi.nlm.nih.gov/36344654
Autor:
Susana M. Campos, Suzanne Berlin, Carolyn N. Krasner, Christin Whalen, Tina Atkinson, Kristin Meegan, Lauren Pereira, Karin Tyburski, Weixiu Lou, Hang Lee, Neil Horowitz, Richard T. Penson
Publikováno v:
Cancer chemotherapy and pharmacology. 89(3)
Temsirolimus, a mTOR inhibitor, and AZD2171, a VEGFR inhibitor, have independently shown activity in patients with gynecological malignancies. Understanding the pivotal role of the PI3K/PTEN/AKT/mTOR pathway in regulating angiogenesis, a phase I stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::857e5ee32f54cfb6ff73892147ab078d
https://pubmed.ncbi.nlm.nih.gov/35142863
https://pubmed.ncbi.nlm.nih.gov/35142863
Autor:
Joyce F. Liu, S. K. Kelley, J. R. Infante, Daniel J. Maslyar, Katie Wood, Brian M. Wolpin, Ursula A. Matulonis, J. Xu, Michael J. Birrer, H. A. Burris, Kirsten Achilles Poon, Walter C. Darbonne, Kathleen N. Moore, YounJeong Choi, Suzanne Berlin, Yulei Wang, Robert Kahn, Mark R. Lackner, Xuyang Lu, Eric W. Humke, Ron Firestein
Publikováno v:
Annals of Oncology, 27(11), 2124. Oxford University Press
Background MUC16 is a tumor-specific antigen overexpressed in ovarian (OC) and pancreatic (PC) cancers. The antibody–drug conjugate (ADC), DMUC5754A, contains the humanized anti-MUC16 monoclonal antibody conjugated to the microtubule-disrupting age
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ac59c52b04eec424c73cc3e1e5cb370
https://doi.org/10.1093/annonc/mdw401
https://doi.org/10.1093/annonc/mdw401
Autor:
William C. Faquin, Emily E. Meserve, Vânia Nosé, A. Afrogheh, Suzanne Berlin, Antonia E. Stephen, Peter M. Sadow
Publikováno v:
Endocrine Pathology. 27:213-219
Tumor-to-tumor metastasis is rare. Herein, we present a unique case of endometrial endometrioid adenocarcinoma metastatic to a thyroid Hürthle cell adenoma 9 years after initial diagnosis. On histologic examination of the thyroid, the malignant endo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ceb304f47182b223a90a1a1afe0540f
https://doi.org/10.1007/s12022-015-9412-5
https://doi.org/10.1007/s12022-015-9412-5
Autor:
Suzanne Berlin, Ursula A. Matulonis, Neil S. Horowitz, Cheryl A. Sadow, Michael G. Muto, Ross S. Berkowitz, Colleen M. Feltmate, Hang Lee, S. M. Campos, Akila N. Viswanathan
Publikováno v:
Gynecologic Oncology. 132:55-60
Objectives To determine the toxicity and survival rates in a trial of concurrent bevacizumab and external beam radiation (EB) for patients with recurrent endometrial or ovarian cancer. Methods Nineteen women with recurrent endometrial ( n =15) or ova
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afe0756653373ca9a45d31f4c79a6d4b
https://doi.org/10.1016/j.ygyno.2013.10.031
https://doi.org/10.1016/j.ygyno.2013.10.031
Autor:
Michael J. Birrer, Suzanne Berlin, Dror Harats, Susana M. Campos, Richard T. Penson, Tamar Rachmilewitz Minei, Yael C Cohen
Publikováno v:
Journal of Clinical Oncology. 37:5542-5542
5542 Background: VB-111 is a targeted anti-cancer gene therapy with a dual mechanism: anti angiogenic/vascular disruption and induction of an anti-tumor directed immune response. We report final results of a phase I/II study of VB-111 in combination
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8371a25555c4e755c0b9912156551f95
https://doi.org/10.1200/jco.2019.37.15_suppl.5542
https://doi.org/10.1200/jco.2019.37.15_suppl.5542
Autor:
Maria Roche, Christin Whalen, Suzanne Berlin, Jackie Szymonifka, Karin Tyburski, Ursula A. Matulonis, L. Pereira, Neil S. Horowitz, Susana M. Campos, Richard T. Penson
Publikováno v:
Gynecologic Oncology. 128:215-220
Objective Ovarian cancer is a highly angiogenic tumor and a model for antiangiogenic research. The tyrosine kinase receptor inhibitors target several receptors allowing for the pharmacological disruption of several independent pathways. Sunitinib mal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cd3928ee9ef0f5d7db238d090f7353a
https://doi.org/10.1016/j.ygyno.2012.07.126
https://doi.org/10.1016/j.ygyno.2012.07.126
Autor:
Merily M Mosquera, Neil S. Horowitz, Suzanne Berlin, Ursula A. Matulonis, L. Pereira, Susana M. Campos, Michael G. Muto
Publikováno v:
Journal of Psychosocial Oncology. 30:387-401
Malignant ovarian neoplasms represent the leading cause of death in gynecological malignancies. Although the majority of ovarian neoplasms occur in women of advanced years, ovarian neoplasms can occur in women of the reproductive age group. Preservat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43a94883524cfd42589a93cb14570a00
https://doi.org/10.1080/07347332.2012.684854
https://doi.org/10.1080/07347332.2012.684854
Autor:
T. Atkinson, Joyce F. Liu, Ursula A. Matulonis, Julie Lee, Margaret Hill, Christin Whalen, Suzanne Berlin, Susana M. Campos, L. Pereira, Hang Lee
Publikováno v:
Gynecologic Oncology. 126:41-46
Objective Test the safety and efficacy of sequentially blocking angiogenesis by adding oral cyclophosphamide to bevacizumab following cancer progression on bevacizumab in patients with recurrent ovarian cancer. Methods Eligibility included ≤2 lines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a6f01d760f1ba3163246a36821c02a0
https://doi.org/10.1016/j.ygyno.2012.04.003
https://doi.org/10.1016/j.ygyno.2012.04.003